{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216731","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2026-05-11T20:05:17+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:53:13.220840+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028","bullets":["Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.","Positive combo data with enzalutamide: median rPFS 7.0 mo overall, 10.1 mo in 1 prior ARPI.","Pivotal Phase 3 protocol for roxadustat in LR-MDS being finalized after FDA feedback; trial start H2 2026.","Revenue $3.7M (up from $2.7M); net loss $15.1M vs $16.8M YoY.","Cash and equivalents $100.3M; sufficient to fund operations into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216731","json":"https://secwatch.observer/filing/0001193125-26-216731.json","markdown":"https://secwatch.observer/filing/0001193125-26-216731.md","text":"https://secwatch.observer/filing/0001193125-26-216731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/0001193125-26-216731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:53:13.220840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b9f3943488d3a014cbe84d684aa8c523d4d0d23","claim":"KYNTRA BIO, INC. reported first quarter 2026 results: revenue $3.7 million, net income $15.1 million, or $3.74 net loss per basic and diluted share, EPS $3.74 net loss per basic and diluted share.","evidence_excerpt":"Total revenue from continuing operations for the first quarter of 2026 was $3.7 million, as compared to $2.7 million for the first quarter of 2025. • Net loss from continuing operations for the first quarter of 2026 was $15.1 million, or $3.74 net loss per basic and diluted share, compared to a net loss of $16.8 million, or $4.15 net loss per basic and diluted share, one year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/0001193125-26-216731-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$3.7 million"},{"label":"Net income","value":"$15.1 million, or $3.74 net loss per basic and diluted share"},{"label":"EPS","value":"$3.74 net loss per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}